Lastly, Oregovomab (originally from B43.13 [261,262]) was tested in patients with ovarian cancer in Phase II trial (NCT01616303), resulting in an improved overall survival with induced CA125-specific T cell production [263,264] and is currently being tested in Phase III trial (NCT04498117). This evidence concerns the gene MUC16 and ovarian carcinoma.